Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar Therapeutics Will Cut 70% of Its Staff After Trial Failure
09:19am, Tuesday, 26'th Apr 2022
The biotech Nektar Therapeutics aims to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers Squibb.
Nektar to reduce workforce by 70%
08:53am, Tuesday, 26'th Apr 2022
Shares of Nektar Therapeutics NKTR, +3.51% were down 5.7% in premarket trading on Tuesday, the day after the company said it will lay off 70% of its workforce. As of Dec. 31, the company employed 740
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan
08:30am, Friday, 22'nd Apr 2022
SAN FRANCISCO , April 22, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacifi
Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More
04:54pm, Wednesday, 20'th Apr 2022 Zacks Investment Research
Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Why Nektar Shares Are Down Almost 35%
03:40pm, Monday, 18'th Apr 2022 Benzinga
Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in col
Why Nektar Therapeutics Stock Is Crashing Today
03:30pm, Monday, 18'th Apr 2022 The Motley Fool
The company is throwing in the towel on its lead pipeline program.
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
02:04pm, Monday, 18'th Apr 2022 Benzinga
Upgrades
For PBF Energy Inc (NYSE:PBF), Scotiabank upgraded the previous rating of Sector Underperform to Sector Perform. For the fourth quarter, PBF Energy had an EPS of $1.28, compared to year-ago q
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
01:32pm, Monday, 18'th Apr 2022 Zacks Investment Research
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog
Expert Ratings for Nektar Therapeutics
01:24pm, Monday, 18'th Apr 2022 Benzinga
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
3
1
0
L
Why Nektar Therapeutics Stock Is Crashing Today
11:30am, Monday, 18'th Apr 2022
The company is throwing in the towel on its lead pipeline program.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
11:17am, Monday, 18'th Apr 2022
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog
Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo
10:39am, Monday, 18'th Apr 2022
Shares of Nektar Therapeutics Inc. NKTR, -34.98% were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Mye
Nektar Therapeutics Stock Tanks Nearly 40%
09:48am, Monday, 18'th Apr 2022
Nektar Therapeutics is ending development of its cancer drug bempeg after the failure of two more trials of the drug in combination with Bristol Myers Squibb's Opdivo.
Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program
09:01am, Monday, 18'th Apr 2022
Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb Co (NYSE: BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.
Nektar stops clinical trials for key cancer drug, shares tumble
07:19pm, Thursday, 14'th Apr 2022
Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after-market tr
